Bayzed Health Group Inc
佰澤醫療集團
(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 2609)

CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT; AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT

The board (the "**Board**") of directors (the "**Director(s)**") of Bayzed Health Group Inc (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Ms. Fong Christine Haiman ("**Ms. Fong**") has tendered her resignation as (i) the joint company secretary of the Company (the "**Joint Company Secretary**"); (ii) an authorised representative of the Company (the "**Authorised Representative**") for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"); and (iii) the representative for acceptance of service of process and notices on behalf of the Company in Hong Kong as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "**Process Agent**") with effect from July 21, 2026. Mr. Yao Le ("**Mr. Yao**") will continue to act as the other Joint Company Secretary and Dr. Chen Haoyang will continue to act as the other Authorised Representative.

Ms. Fong has confirmed that she has no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to her resignation.

Following the resignation of Ms. Fong, Mr. Tsang Chun Ho ("**Mr. Tsang**") has been appointed as the Joint Company Secretary, the Authorised Representative and the Process Agent with effect from July 21, 2026.

The biographical details of Mr. Yao and Mr. Tsang are set out as follows:

Mr. YAO Le (姚樂), joined the Group in January 2019, and is currently the vice president, chief financial officer, secretary to the Board and Joint Company Secretary of the Group.

Mr. Yao has over 15 years of working experience in financial management of large enterprises, capital markets and the healthcare industry. He worked as an officer of the financial management department (財務管理部門職員) at the Founder Group (北大方正集團有限公司) from July 2010 to June 2012, and as a finance manager (財務經理) from November 2013 to February 2016, in which he was responsible for a variety of financial management matters. He then joined Founder Financing Services LLC* (方正證券承銷保薦有限責任公司) in March 2016 as a vice president of the investment banking division, in which he was responsible for the initial public offering, restructuring, and merger and acquisition projects, and he stayed in the position until December 2017. From December 2017 to December 2018, Mr. Yao served as the general manager of the investment department of Beijing Baicheng Baixin Technology Limited* (北京佰誠佰欣科技有限公司). From January 2019 to March 2020, he served as the assistant president of the Company, responsible for the Group's investment management matters. From April 2020 to March 2022, he served as the vice president of the Company and the general manager of Anhui Shoukang Medical Investment Company Limited (安徽首康醫療投資有限公司), responsible for its investment and the operation and management of its subsidiaries. Since April 2022, he has served as the vice president and chief financial officer of Bayzed Medical Investment Group Company Limited* (佰澤醫療投資集團有限公司), and various positions in the Group, which include, among others, being director at ten of the Group's subsidiaries.

Mr. Yao was appointed as the Joint Company Secretary of the Company on October 14, 2025. Mr. Yao holds a master's degree in accounting and financial management from the University of York (約克大學) in the United Kingdom, and he also obtained his executive master's degree of business administration from Peking University in July 2024.

Mr. Tsang is a Manager of Company Secretarial Services of Tricor Services Limited, a member of Vistra Group. Mr. Tsang has over 12 years of experience in the company secretarial field, and has served various listed companies in Hong Kong, as well as multinational corporations, private companies and offshore companies by providing them with professional corporate services. Mr. Tsang is currently the joint company secretary of Shanghai Biren Technology Co., Ltd. (Stock Code: 6082).

Mr. Tsang is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Mr. Tsang obtained a Bachelor of Arts degree from the University of Huddersfield in the United Kingdom in December 2017, and a Master of Corporate Governance degree from the Hong Kong Metropolitan University in November 2021.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Listing Rules, an issuer must appoint a company secretary who satisfies the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that the company secretary of a listed issuer must be an individual who, by virtue of his academic or professional qualifications or relevant experience, is in the opinion of the Stock Exchange capable of discharging the functions of a company secretary.

Although Mr. Yao currently does not possess the specified qualifications of a company secretary as required under Note 1 to Rule 3.28 of the Listing Rules, given Mr. Yao's academic qualification and work experience, the Company has applied for, and the Stock Exchange has granted a waiver (the "**Waiver**") to the Company from strict compliance with Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Mr. Yao to act as a Joint Company Secretary for a period from the date of appointment of Mr. Tsang as a Joint Company Secretary to 13 October 2028 (the "**Remaining Waiver Period**"), subject to the following conditions:

(i) Mr. Yao must be assisted by Mr. Tsang during the Remaining Waiver Period; and

(ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

The Stock Exchange may withdraw or change the Waiver if the Company's situation changes.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Fong for her valuable contribution to the Company during her tenure of office, and welcome Mr. Tsang on his new appointment.

By order of the Board
Bayzed Health Group Inc
(佰澤醫療集團)
Dr. Chen Haoyang
Chairman and Executive Director

Hong Kong, July 21, 2026

As at the date of this announcement, the Board comprises executive Directors of Dr. Chen Haoyang, Mr. Lyu Chao, Ms. Xu Xu, Mr. Lu Jizhong and Mr. Feng Yu; and independent non-executive Directors of Mr. Chan Hok Leung, Ms. Liu Shuang and Dr. Guo Wei.

* *For identification purposes only*